Allergan to Acquire Vitae Pharmaceuticals Adding Innovative Development Programs for Dermatologic Conditions

DUBLIN and FORT WASHINGTON, Pa., Sept. 14, 2016 -- Allergan plc (AGN), a leading global pharmaceutical company, and Vitae Pharmaceuticals, Inc. (VTAE), a clinical-stage biotechnology company, today announced that they have entered into a definitive agreement under which Allergan will acquire Vitae for $21.00 per share, in cash, for a total transaction value of approximately $639 million. The Boards of Directors of both companies have unanimously approved the transaction.

The acquisition will strengthen Allergan's dermatology product pipeline, with the addition of VTP-43742, a Phase 2 first-in-class, orally active RORγt (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis and other autoimmune disorders. VTP-43742 acts through the potent inhibition of IL-17 activity. In preclinical studies, VTP-43742 has been observed to inhibit RORγt activity, is highly selective versus other ROR isotypes and may provide a treatment that could be administered as a once-daily oral dose. The compound recently completed a Phase 2 proof-of-concept multiple ascending dose trial in patients with moderate to severe psoriasis.

Published: 14 September 2016

Written by Editor

Nasdaq M & A Up on News

Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea

REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 12, 2016 -- Foamix Pharmaceuticals Ltd. (FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the topline results of its Phase 2 clinical trial of FMX103 for the treatment of papulopustular rosacea. Statistically significant differences were demonstrated for improvement in the primary and secondary efficacy endpoints (reduction in the number of inflammatory lesions – papules and pustules and improvement of Investigator Global Assessment score) for FMX103 compared with the vehicle-treated group.

"We are extremely encouraged that our Phase 2 dose-finding study demonstrated that FMX103 appears to be safe and effective in the treatment of moderate-to-severe papulopustular rosacea," said Dov Tamarkin, Ph.D., CEO of Foamix.

Published: 12 September 2016

Written by Editor

Nasdaq Up on News Project Update

Horizon Pharma plc to Acquire Raptor Pharmaceutical Corp. as Further Step in Building Leading Rare Disease Business

- Transaction valued at $9.00 per share in cash with fully diluted equity value of approximately $800 million -

- Transaction is expected to be accretive to adjusted EBITDA in 2017 -

- Conference call today at 8 a.m. ET to discuss transaction -

DUBLIN, Ireland and NOVATO, Calif., Sept. 12, 2016 -- Horizon Pharma plc (HZNP) and Raptor Pharmaceutical Corp. (RPTP) today announced the companies have entered into a definitive agreement under which Horizon Pharma will acquire all of the issued and outstanding shares of Raptor Pharmaceutical Corp. common stock for $9.00 per share in cash, for an implied fully diluted equity value of approximately $800 million. The transaction is expected to close in the fourth quarter of 2016.

Published: 12 September 2016

Written by Editor

Nasdaq M & A Up on News

Apollo Endosurgery and Lpath Sign Merger Agreement

AUSTIN, Texas and SAN DIEGO, Sept. 8, 2016 -- Lpath, Inc. (LPTN) and Apollo Endosurgery, Inc. today announced that they have entered into a definitive merger agreement under which the security holders of Apollo would become the majority owners of Lpath. Under terms of the agreement, Lpath will issue new shares of its common stock or rights to acquire its common stock to Apollo security holders. The Apollo security holders are expected to own approximately 95.8 percent of the combined company and the Lpath security holders are expected to own approximately 4.2 percent of the combined company, subject to adjustments as described in the merger agreement.

Concurrent with the closing of the merger, Apollo's major investors have committed to invest approximately $29 million of new equity in the combined company, which will form part of the Apollo 95.8 percent ownership. The major investors include affiliates of PTV Healthcare Capital, H.I.G. BioHealth Partners, Remeditex Ventures, Novo A/S, and CPMG Inc. As of June 30, 2016 Apollo's cash was approximately $11.6 million and long term debt was approximately $50 million. Apollo's consolidated revenue for the calendar year ended December 31, 2015 was approximately $68 million.

Published: 09 September 2016

Written by Editor

Nasdaq M & A Up on News

Auris Medical Achieves Midpoint for Enrollment in Phase 3 Trial of AM-111 in Sudden Deafness

ZUG, Switzerland, Sept. 9, 2016 -- Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it has reached the midpoint for enrollment in the HEALOS Phase 3 clinical trial of AM-111 in idiopathic sudden sensorineural hearing loss, or ISSNHL, which is also known as sudden deafness.

"We are pleased to continue making progress with the Phase 3 development of AM-111 as the first specific therapeutic for acute inner ear hearing loss," commented Thomas Meyer, Auris Medical's founder, Chairman and Chief Executive Officer. "HEALOS has now enrolled more than 125 patients out of the target of 255 patients, and we expect to report top-line results in the second half of next year, in line with previous guidance."

Published: 09 September 2016

Written by Editor

Nasdaq Up on News Project Update

Page 65 of 246

Vitae Pharmaceuticals ( VTAE )

Allergan to Acquire Vitae Pharmaceuticals Adding Innovative Development Programs for Dermatologic Conditions

Foamix Pharmaceuticals Ltd ( FOMX )

Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea

Raptor Pharmaceutical Corp ( RPTP )

Horizon Pharma plc to Acquire Raptor Pharmaceutical Corp. as Further Step in Building Leading Rare Disease Business

Lpath Inc ( LPTN )

Apollo Endosurgery and Lpath Sign Merger Agreement

Auris Medical Holding AG ( EARS )

Auris Medical Achieves Midpoint for Enrollment in Phase 3 Trial of AM-111 in Sudden Deafness